Hetero, a city-based leading pharmaceutical company on Monday announced the receipt of World Health Organisation Prequalification of Medicines Programme (WHO PQ) approval for its generic version of COVID-19 oral anti-viral treatment candidate Nirmatrelvir.
About the Author
